Competitive Generic Therapies: Off-Patent Drugs With 1-4 Sources
✉ Email this page to a colleague
This table lists drugs which, despite having no patents or regulatory protections, have a limited number of active sources.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Strength |
---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma Ltd | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 090159-001 | Nov 15, 2018 | AB | RX | No | No | EQ 600MG BASE;300MG |
Chartwell Rx | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 204990-001 | Mar 28, 2017 | AB | RX | No | No | EQ 600MG BASE;300MG |
Cipla | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 091144-001 | Mar 28, 2017 | AB | RX | No | Yes | EQ 600MG BASE;300MG |
Laurus | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 216332-001 | Jul 25, 2022 | AB | RX | No | No | EQ 600MG BASE;300MG |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Strength |